Paricalcitol

Drug Profile

Paricalcitol

Alternative Names: ABT-358; Paracalcin; Zemplar; Zemplar Capsules

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Abbott Laboratories
  • Class Ergocalciferols; Vitamin D analogues
  • Mechanism of Action Calcitriol receptor agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Secondary hyperparathyroidism

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Apr 2015 AbbVie completes a phase III trial in Secondary hyperparathyroidism in Germany, USA and Portugal (NCT01382212)
  • 01 Oct 2013 First generic equivalent available in USA for Secondary hyperparathyroidism (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top